...was in Phase III testing. Mitsubishi has global rights to develop AST-120 for CKD from Kureha...
...from Kureha for liver and gastrointestinal diseases. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Kureha Corp....

...initiation of dialysis, kidney transplantation or doubling of serum creatinine levels vs. placebo. Mitsubishi and Kureha...
...in San Diego in November. Mitsubishi has global rights to develop AST-120 for CKD from Kureha...
...from Kureha for liver and gastrointestinal diseases. Mitsubishi Tanabe Pharma Corp. (Tokyo:4508; Osaka:4508), Osaka, Japan Kureha Corp....

...where the product is in Phase II testing for non-constipating IBS. Ocera licensed Zysa from Kureha Corp....

...were presented at the Digestive Disease Week meeting in New Orleans. Ocera licensed AST-120 from Kureha Corp....

...not currently enough to get approved," he said. Ocera licensed ex-Asian rights to AST-120 from Kureha Corp....
...Osaka:4568), Tokyo, Japan Harvard Medical School , Cambridge, Mass. Johns Hopkins University , Baltimore, Md. Kureha Corp....

...grams oral AST-120 given thrice daily for up to 8 weeks. Ocera licensed AST-120 from Kureha Corp....

...three times daily for 8 weeks in up to 150 patients. Ocera licensed AST-120 from Kureha Corp....

...rights to AST-120 to treat GI and liver diseases. The candidate was from Japanese company Kureha...
...and Korea. In May 2006, Ocera released Phase III data from a trial run by Kureha...

...Ocera in-licensed the oral nanoporous microsphere agent, which absorbs toxins from the gastrointestinal tract, from Kureha...

...tract, is in a Phase II trial to treat active pouchitis. Ocera licensed AST-120 from Kureha Corp....